Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience-Reference-Cited by-同舟云学术

Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience

Published:2021-11-11 Issue:2 Volume:101 Page:349-358
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Wang Yu-Wen,Tsai Xavier Cheng-Hong,Hou Hsin-An,Tien Feng-Ming,Liu Jia-Hau,Chou Wen-Chien,Ko Bor-Sheng,Chen Yu-Wen,Lin Chien-Chin,Cheng Chieh-Lung,Lo Min-Yen,Lin Yun-Chu,Lu Li-Chun,Wu Shang-Ju,Kuo Sung-Hsin,Hong Ruey-Long,Huang Tai-Chung,Yao Ming

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-021-04711-9.pdf

Reference37 articles.

1. Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ (2020) Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 38(2):155–165. https://doi.org/10.1200/JCO.19.00172

2. Sehn LH, Salles G (2021) Diffuse large B-cell lymphoma. N Engl J Med 384(9):842–858. https://doi.org/10.1056/NEJMra2027612

3. Maurer MJ, Ghesquieres H, Jais JP, Witzig TE, Haioun C, Thompson CA, Delarue R, Micallef IN, Peyrade F, Macon WR, Jo Molina T, Ketterer N, Syrbu SI, Fitoussi O, Kurtin PJ, Allmer C, Nicolas-Virelizier E, Slager SL, Habermann TM, Link BK, Salles G, Tilly H, Cerhan JR (2014) Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol 32(10):1066–1073. https://doi.org/10.1200/JCO.2013.51.5866

4. Mounier N, El Gnaoui T, Tilly H, Canioni D, Sebban C, Casasnovas RO, Delarue R, Sonet A, Beaussart P, Petrella T, Castaigne S, Bologna S, Salles G, Rahmouni A, Gaulard P, Haioun C (2013) Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica 98(11):1726–1731. https://doi.org/10.3324/haematol.2013.090597

5. Vacirca JL, Acs PI, Tabbara IA, Rosen PJ, Lee P, Lynam E (2014) Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Ann Hematol 93(3):403–409. https://doi.org/10.1007/s00277-013-1879-x

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utilization of Real-World Data to Facilitate Clinical Trials for Patients with Lymphoma;Pharmacoepidemiology;2024-08-06

2. A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS);Frontiers in Pharmacology;2024-06-25

3. A real-world pharmacovigilance analysis of the FDA adverse event reporting system events for polatuzumab vedotin;Expert Opinion on Drug Safety;2024-05-02

4. Poor outcomes for trial‐ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B‐cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project;eJHaem;2024-02-23

5. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review;Current Cancer Therapy Reviews;2024-01